Theravance Biopharma TBPH Accrued Clinical And Development Expenses Current
Accrued Clinical And Development Expenses Current at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept tbph:AccruedClinicalAndDevelopmentExpensesCurrent.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's accrued clinical and development expenses current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's accrued clinical and development expenses current?
- Theravance Biopharma (TBPH) reported accrued clinical and development expenses current of $2.4M in Q1 2026.
- How has Theravance Biopharma's accrued clinical and development expenses current changed year-over-year?
- Theravance Biopharma's accrued clinical and development expenses current decreased by 2.5% year-over-year, from $2.46M to $2.4M.
- What is the long-term trend for Theravance Biopharma's accrued clinical and development expenses current?
- Over 5 years (2020 to 2025), Theravance Biopharma's accrued clinical and development expenses current has grown at a -34.9% compound annual growth rate (CAGR), from $28.8M to $3.37M.
- What does accrued clinical and development expenses current mean?
- This reflects the estimated costs incurred for clinical trials and research activities that have not yet been invoiced or paid by the company. It is a critical measure of the company's ongoing R&D operational intensity and short-term financial obligations related to drug development. Tracking this helps analysts understand the burn rate and the timing of cash outflows for pipeline advancement.